ALA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 20.78%

Insider Buying (Last 12 Months): A$98,839.76

Insider Selling (Last 12 Months): A$0.00

Arovella Therapeutics Insider Trading History Chart

Arovella Therapeutics Share Price & Price History

A^$0.00

+0.30 (1.20%)

As of 11/16/2021 10:05 AM ET

Brace Yourself: Experts calling for Bitcoin to hit $100k

From Crypto 101 Media | Ad

For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.

Click here to get The Crypto Bull Run Millionaire Blueprint now.

Arovella Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/27/2024	Michael Baker	Insider	Buy	220,000	A$0.14	A$31,240.00
12/29/2023	Michael Baker	Insider	Buy	587,824	A$0.12	A$67,599.76
8/24/2023	Thomas (Tom) Duthy	Insider	Issued	6,521,739	A$0.05	A$299,999.99
7/12/2023	Thomas (Tom) Duthy	Insider	Issued	444,444	A$0.05	A$19,999.98
5/5/2023	Elizabeth Stoner	Insider	Issued	500,000	A$0.02	A$10,000.00
12/15/2022	David Simmonds	Insider	Issued	1,600,000	A$0.03	A$40,000.00
12/2/2022	Michael Baker	Insider	Issued	1,586,842	A$0.04	A$60,300.00
3/16/2022	Paul Hopper	Insider	Issued	631,578	A$0.04	A$23,999.96
12/16/2021	Paul Hopper	Insider	Issued	6,000,000	A$0.04	A$240,000.00
11/11/2021	Michael Baker	Insider	Issued	8,000,000	A$0.04	A$328,000.00

Brace Yourself: Experts calling for Bitcoin to hit $100k

From Crypto 101 Media | Ad

For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.

Click here to get The Crypto Bull Run Millionaire Blueprint now.

SEC Filings (Institutional Ownership Changes) for Arovella Therapeutics (ASX:ALA)

8.21% of Arovella Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

1.23%

Beta

N/A

Who are the company insiders with the largest holdings of Arovella Therapeutics?: Arovella Therapeutics' top insider shareholders include:
David Simmonds (Insider)
Elizabeth Stoner (Insider)
Michael Baker (Insider)
Thomas (Tom) Duthy (Insider)
Learn More about top insider investors at Arovella Therapeutics.